Fundraising Fox

Orthobond

Monmouth Junction, US · Delaware corporation · 1 known investors

Orthobond develops proprietary antimicrobial nanosurface technology that covalently binds to metallic and polymeric surfaces to mechanically kill bacteria, viruses, and fungi without antibiotics or eluting chemicals. Its first products, including Ostaguard, are antimicrobial surface treatments for implantable medical devices, with intended future applications in textiles, consumer goods, and high-touch public surfaces.

HealthtechMedical DevicesNew Materials

Founders & leadership

DNDavid Nichols
David NicholsinCEO
PG
Peter GoodwinNamed on SEC filing
FC
Frank CammisaNamed on SEC filing
KB
Khalil BarrageNamed on SEC filing
LD
Lisa D'UrsoNamed on SEC filing
DH
David HelfetNamed on SEC filing
PK
Peter K. ScaturroNamed on SEC filing
GL
Gregory LutzNamed on SEC filing
PV
Paul VolovichNamed on SEC filing
AP
Anna Paulina LutzNamed on SEC filing
KG
Kenneth GallNamed on SEC filing
PM
Pritam MishraNamed on SEC filing

Investors · 1

Kineticos DisruptorreportedRaleigh

Reported raises · per SEC filings

Form D private placements

$1.1M disclosed across 1 round · 2022

▶$8.3MraisedSep 2026 · 24 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • David NicholsExecutive Officer, Director
  • Khalil BarrageDirector
  • Frank CammisaDirector
  • David HelfetDirector
  • Anna Paulina LutzDirector
  • Peter ScaturroDirector
  • Lisa D'UrsoDirector
  • Kenneth GallDirector
  • Shailesh MaingiDirector
  • Pritam MishraDirector
  • Eric MajorDirector
  • Greg ColeDirector
Offering amount
$10M
Amount sold
$8.3M
Minimum investment
$25K
Sales commissions
$475K
Placement agents
Lucid Capital Markets, Castle Hill Partners Inc.
First sale
Aug 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.1MraisedSep 2022 · 8 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • David NicholsExecutive Officer, Director
  • Peter GoodwinDirector
  • Frank CammisaDirector
  • Khalil BarrageDirector
  • Lisa D'UrsoDirector
  • David HelfetDirector
  • Peter K. ScaturroDirector
  • Gregory LutzDirector
  • Paul VolovichExecutive Officer
Offering amount
$15M
Amount sold
$1.1M
Minimum investment
$50K
Sales commissions
$750K
Placement agents
Kola Agbaje
First sale
Sep 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap
OrthoFi8 shared keywordsOrthoFi provides software and services for orthodontic and dental practices, covering patient onboarding, insurance verification and claims processing, patient financing, and accounts receivable collections. Its products, including AcceptCare and OrthoBanc, help practices increase case acceptance, offer flexible payment options to patients, and manage cash flow.
Brainly6 shared keywordsBrainly provides 1:1 tutoring combining AI explanations with human expert intervention, targeting K-12 students and their parents seeking affordable academic support across all subjects. The platform emphasizes guaranteed grade improvement within 30 days, safety through human supervision of AI interactions, and compliance with education-focused privacy standards.

Companies competing with Orthobond for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2022$146.4K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Kineticos Life Sciences Partners and Invests in Orthobondfinance.yahoo.com · Sep 2024CCIT Graduate Orthobond Corporation Turns to State Support in Quest to Improve Patients’ Health and Lifestyle - NJEDAnjeda.gov · Mar 2016

Frequently asked questions

What does Orthobond do?
Orthobond develops proprietary antimicrobial nanosurface technology that covalently binds to metallic and polymeric surfaces to mechanically kill bacteria, viruses, and fungi without antibiotics or eluting chemicals. Its first products, including Ostaguard, are antimicrobial surface treatments for implantable medical devices, with intended future applications in textiles, consumer goods, and high-touch public surfaces.
Who are Orthobond's investors?
Orthobond's investors include Kineticos Disruptor.
How much funding has Orthobond raised?
Orthobond has disclosed $1.1M raised across 1 round.
Where is Orthobond headquartered?
Orthobond is headquartered in Monmouth Junction, US.